ATAI Life Sciences aims to transform mental health care, backing companies working on new treatments for depression, anxiety and addiction. Now, it’s adding digital tools to the mix through a new company called IntroSpect Digital Therapeutics.
ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
JOIN THE ATAI #INSIGHTNETWORK